Azithromycin Reduction to Reach Elimination of Trachoma (ARRET)
Trachoma
About this trial
This is an interventional treatment trial for Trachoma
Eligibility Criteria
Inclusion Criteria:
- Provision of appropriate informed consent
- Stated willingness to comply with all study procedures
- Live in one of the 80 communities with up to 20% prevalence of TF selected for the trial
Exclusion Criteria:
- Does not consent to participation
- Unwilling to comply with all study procedures
- Does not live in one of the 80 communities with up to 20% prevalence of TF selected for the trial
Sites / Locations
- Programme National de Santé Oculaire (PNSO)Recruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
No Intervention
Azithromycin Continuation
Azithromycin Discontinuation
In study communities randomized to the Azithromycin Continuation arm, all individuals aged 1 month and older will receive a single mass distribution of azithromycin several weeks after the baseline and 36-month monitoring visits. Oral azithromycin, 20 mg/kg for children and 1 g for adults, will be offered to all households identified on the preceding census in the communities randomized to continuing treatment. Study drug will be distributed by health extension workers and organized by PNSO. Individuals with a known macrolide allergy will be offered a two-week course of daily ophthalmic tetracycline ointment (two tubes).
In study communities randomized to the Azithromycin Discontinuation arm, individuals will receive no treatment.